Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,795.3 | 154.71 | 4,26,517.78 | 863.29 | 0.76 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,998.35 | 86.35 | 1,58,636.06 | 518 | 0.5 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,486.5 | 27.95 | 1,18,365.23 | 1,178.16 | 0.89 | 3,969.86 | 360.74 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.1 | 64.22 | 1,05,067.36 | 460 | 0.9 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,551.6 | 51.02 | 1,02,273.02 | 634.43 | 0 | 2,529.74 | 269.23 |
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice